Marie Bosslett, Assistant Editor

Learn more about the in-depth topics covered in the February 2025 print issue of Dermatology Times.

Belgian patients receiving biologics had faster response rates compared to phototherapy, systemic, and topical treatments.

Dermatology Times is looking back on the top stories in dermatology from the month of February.

After just 2 weeks of twice-daily use, a pediatric patient saw visually improved skin with no adverse events.

Nonsteroidal AD therapies are gaining attention due to their rapid effectiveness and ability to offer an alternative to long-term steroid use.

Haws offers advice to female clinicians about leadership, collaboration, and the future of the aesthetics industry.

A two-set Mendelian randomization analysis revealed a genetic correlation between depression and androgenetic alopecia.

A PDUFA target action date has been set for October 13, 2025.

This collective initiative gives Mindy Haws, MD, and her team the ability to reach more women in a way that gives back and helps them succeed.

The case-control Chinese study evaluated circumstances that have previously never been established as potential melasma causes.

Mindy Haws, MD, spoke to Dermatology Times about the new videos, podcasts, and other resources LIMITLESS offers for women at all stages of their careers.

Although more research is needed to fill this gap, sunscreen had the greatest success rates of all the prevention methods in this literature review.

In case you missed it, this week we had news about Arcutis’ new seborrheic dermatitis initiative with Odell Beckham Jr., Zabalafin’s IND for atopic dermatitis, dupilumab as a potential BP treatment, and more.

Satisfaction levels rose and recovery outcomes greatly improved with Cicaglocal compared to the placebo.

The combination treatment safely and quickly reduced laser-induced hyperpigmentation, especially on darker skin tones.

Symptoms of rosacea and dependence on oral medication were reduced in all 5 case studies.

Patients aged 6 to 12 had little to no adverse events and no pharmacokinetic abnormalities were noted.

The co-founder of PathAI and its PathAssist Derm tool believes AI is going to be incredibly valuable for dermatologists and dermatopathologists.

Alphyn’s therapy uniquely treats both the immune system and bacterial components of atopic dermatitis.

Positive results in melanin, erythema, wrinkles, texture, and periorbital dermal thickness were observed during the 8-week study.

Although the tool is currently designed for research use only, CEO Andy Beck, MD, PhD, is excited about its future in clinical dermatopathology.

“I think some key things that stand out to me are that it's safe, effective, backed by rigorous clinical data, and has very high patient satisfaction,” Watchmaker said about the new product.

Michael Rubio, PA-C, and Renata Block, MMS, PA-C discuss the complexities associated with practicing telemedicine, especially as a PA.

In case you missed it, this week we had news about rezpegaldesleukin’s fast track designation for AD, bimekizumab’s long-term efficacy for HS, conference recaps of SBS and MOPD, and more.

Adelaide A. Hebert, MD, FAAD, stressed the importance of educating patients, setting realistic expectations, and ensuring they adhere to AD treatment plans.

Michael Rubio, PA-C talks with Renata Block, MMS, PA-C, about his virtual care platform and how it can expand access to care.

Renata Block, MMS, PA-C, and Michael Rubio, PA-C discuss the complexities of developing a telehealth program in the world of dermatology.

The state-of-the-art facilities in California, Georgia, and Texas will expand AMI’s curriculum to providers of all levels.

Clinicians observed a positive relationship between scalp hair regrowth and downstream treatment benefits for patients with alopecia areata.

Each treatment saw very mild clinical and dermatologic responses with low levels of patient satisfaction.